- FDA approves generic versions of Plavix
- FDA OKs Abilify as maintenance treatment for bipolar disorder
- As innovaters prep for patent cliff, generics prosper from patent losses
- FDA gives new approval to Bristol-Myers Squibb's, Lilly's Erbitux
- Bristol-Myers Squibb, Gilead Sciences to develop, commercialize HIV combo treatment
NEW YORK — Bristol-Myers Squibb has completed its acquisition of a developer of hepatitis C treatments.
Bristol said it successfully completed its tender offer for all of the outstanding shares of common stock of Alpharetta, Ga.-based Inhibitex, at a purchase price of $26 per share via a “short form merger” in which all such shares were converted into the right to receive the aforementioned share price in cash and without interest, less any applicable withholding taxes.
Bristol said it intends to delist and de-register Inhibitex common stock as promptly as practicable following the effective time of the merger.